A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

Trial Profile

A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Emixustat (Primary)
  • Indications Stargardt disease
  • Focus Pharmacodynamics
  • Sponsors Acucela
  • Most Recent Events

    • 26 Jan 2017 Status changed from planning to recruiting, as per an Acucela media release.
    • 13 Jun 2016 According to an Acucela Inc. media release, the company plans to initiate this trial by the end of 2016.
    • 27 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top